Bayer Aktiengesellschaft (BIT:1BAYN)
Italy · Delayed Price · Currency is EUR | Market Cap | 36.77B +66.5% |
| Revenue (ttm) | 45.58B -2.2% |
| Net Income | -3.62B |
| EPS | -3.68 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.81 |
| Dividend | 0.11 (0.29%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 36,573 |
| Average Volume | 18,441 |
| Open | 38.57 |
| Previous Close | 38.70 |
| Day's Range | 37.31 - 38.57 |
| 52-Week Range | 22.07 - 49.70 |
| Beta | 0.89 |
| RSI | 41.55 |
| Earnings Date | May 12, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial StatementsNews
Bayer reports REVEAL study met primary endpoints
Bayer (BAYRY) announced topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evu...
Bayer to acquire Perfuse Therapeutics for $300M upfront
Bayer (BAYRY) and Perfuse Therapeutics announced an agreement under which Bayer will fully acquire Perfuse Therapeutics. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a...
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women's Hospital that evaluated...
Bayer and bp Form Strategic Alliance to Jointly Scale Camelina as Intermediate Crop for Biofuels
ST. LOUIS--(BUSINESS WIRE)--Bayer, a life science company, and bp, a global integrated energy company, today announced that they have entered into a long-term strategic alliance to jointly scale the c...
Bayer says its experimental blood thinner cuts risk and severity of repeat strokes
Bayer said on Wednesday new analyses showed its experimental blood thinner asundexian reduced the incidence and severity of ischaemic strokes.
Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Bayer said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology pipeline.
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneer...
House strips MAHA-hated pesticide provisions from farm bill
MAHA advocates said the language that was stripped could have provided liability protection for Bayer in lawsuits involving its Roundup weedkiller.
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new la...
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
BERLIN--(BUSINESS WIRE)--A new study from Leaps by Bayer and BCG reveals varying trends in how the public views breakthrough science in China, Germany, and the United States.
Bayer upgraded to Buy from Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded Bayer (BAYRY) to Buy from Neutral with a EUR 56 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial
Trump draws criticism from MAHA base over weed killer glyphosate
The Supreme Court is considering arguments around the broadly used herbicide glyphosate, which is sold by Bayer subsidiary Monsanto as "Roundup." The case will determine whether state laws preempt fed...
Bayer Faces Critical Supreme Court Debate Over Roundup Lawsuits
Bayer Faces Critical Supreme Court Debate Over Roundup Lawsuits
Bayer Faces Supreme Court Challenges Over Roundup Lawsuits (BAYRY)
Bayer Faces Supreme Court Challenges Over Roundup Lawsuits (BAYRY)
Bayer shares slide after U.S. Supreme Court split over Bayer's fight against Roundup lawsuits
Shares in chemicals giant Bayer fell as much as 6.5% on Tuesday after the U.S. Supreme Court appeared split over what view it will form in Bayer's fight against Roundup lawsuits.
Bayer Faces Legal Challenge Over Roundup Liability
Bayer Faces Legal Challenge Over Roundup Liability
With Bayer at US Supreme Court, MAHA rallies against pesticides
"Make America Healthy Again" activists rallied at the U.S. Supreme Court building on Monday against Bayer as the justices heard arguments in the German company's effort to end thousands of lawsuits t...
Bayer Faces Supreme Court Hearing on Roundup Liability
Bayer Faces Supreme Court Hearing on Roundup Liability
US Supreme Court hears Bayer's fight against Roundup lawsuits
The U.S. Supreme Court is set on Monday to consider Bayer AG's effort to shut down thousands of lawsuits accusing the company of failing to warn users that the active ingredient in its Roundup weedki...
Bayer (BAYRY) Faces Supreme Court Hearings on Roundup Lawsuits
Bayer (BAYRY) Faces Supreme Court Hearings on Roundup Lawsuits
Bayer hopes U.S. Supreme Court can rein in Roundup lawsuits, Bloomberg says
Bayer (BAYRY) is hoping the U.S. Supreme Court can reduce or simplify the lawsuits over its Roundup weedkiller and potentially corral litigation that has cost the company over $10B, Jef
Explainer: What does Bayer's US Supreme Court case mean for the thousands of Roundup lawsuits?
The U.S. Supreme Court hears arguments on Monday in Bayer's bid to limit thousands of lawsuits alleging that the German company's Roundup weedkiller causes cancer in a case that is one part of sprawli...
Bayer Advances $7.25 Billion Roundup Settlement Ahead of Key Supreme Court Ruling
Bayer Advances $7.25 Billion Roundup Settlement Ahead of Key Supreme Court Ruling
Buy or Goodbye?: Alphabet, Nestle, Bayer und SAP - Die Analystenstimmen des Tages
Alphabet, Nestle, Bayer und SAP: Die wichtigsten Analysten-Updates im Überblick.